Dr. Martens (LON:DOCS) Stock Price Down 11.6% – What’s Next?

Shares of Dr. Martens plc (LON:DOCS) fell 11.6% during trading on Tuesday . The stock traded as low as GBX 65 and last traded at GBX 66.90. 9,032,986 shares were traded during mid-day trading, an increase of 342% from the average session volume of 2,043,681 shares. The stock had previously closed at GBX 75.65.

More Dr. Martens News

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg Bank reaffirmed its “buy” rating on DOCS, which could provide some analyst support and limit downside from purely sentiment-driven selling. Digital Look London Stock Exchange
• Negative Sentiment: Management projects flat revenue for 2026 and says it is scaling back discounts to protect margins — a signal that underlying demand may be weak. Investors often penalize top‑line stagnation even if margin discipline improves, which helps explain the selloff and high trading volume today. Dr Martens projects flat 2026 revenue as it scales back discounts

Analyst Ratings Changes

Several brokerages recently issued reports on DOCS. Berenberg Bank restated a “buy” rating on shares of Dr. Martens in a research report on Tuesday. Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Dr. Martens currently has a consensus rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Stock Performance

The stock has a market cap of £646.63 million, a price-to-earnings ratio of 39.35, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The stock’s 50-day moving average is GBX 76.53 and its 200-day moving average is GBX 83.47.

Dr. Martens (LON:DOCS) last issued its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Insider Buying and Selling

In other Dr. Martens news, insider Robert Hanson bought 96,000 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was purchased at an average cost of GBX 79 per share, for a total transaction of £75,840. Insiders acquired 97,130 shares of company stock valued at $7,673,816 in the last ninety days. Corporate insiders own 2.79% of the company’s stock.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.